Collegium to Present Pediatric and Real-World Research Across ADHD Portfolio at AACAP and NEI Fall Congresses
Key Highlights
- ➤Seven ADHD portfolio abstracts accepted for AACAP and NEI fall congress presentations
- ➤Phase 4 AZSTARYS studies cover pediatric safety, tolerability, and efficacy
- ➤JORNAY PM analyses examine adult treatment persistence and morning functioning
- ➤Caregiver survey assesses morning functioning and strain across ADHD medication regimens
- ➤Presentations span pediatric trials and real-world ADHD research across ages
Expert Statements
Thomas Smith, M.D., Executive Vice President and Chief Medical Officer, Collegium Pharmaceutical, Inc.
“People living with ADHD, and the families who support them, need care they can count on throughout the day, so they can focus on school, work, and time with the people around them”
Thomas Smith, M.D., Executive Vice President and Chief Medical Officer, Collegium Pharmaceutical, Inc.
“The clinical studies and real-world research we’re presenting this fall help deepen the understanding of those daily needs and advance how ADHD is managed.”
STOUGHTON, Mass., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading biopharmaceutical company focused on improving the lives of people living with serious and often misunderstood conditions, today announced that seven abstracts from its attention-deficit/hyperactivity disorder (ADHD) portfolio have been accepted for presentation at two scientific congresses this fall. The presentations span pediatric clinical studies and research examining daily functioning among adults and caregivers, reflecting Collegium’s commitment to building a broader understanding of ADHD across ages and real-life settings.
The data will be presented at the American Academy of Child and Adolescent Psychiatry (AACAP) 2026 Annual Meeting, taking place October 26–31 in Atlanta, and the Neuroscience Education Institute (NEI) Fall Congress, taking place November 5–8 in Colorado Springs.
Get started
Create a free account to read the full story.